Narcolepsy Type 1 Clinical Trial
— NARCO7TOfficial title:
Contribution of 7 Tesla MRI of the Hypothalamus in the Diagnosis of Type 1 Narcolepsy: Pilot Study
This study is part of the research on type 1 narcolepsy, a neurological pathology affecting mostly young subjects. The only biomarker currently available is the hypocretin assay, which shows a level below 110 pg/mL. However, the interpretation of this biomarker has limitations: the test is not widely available and it is rarely performed by practitioners. Even when performed, the interpretation of the level may not be consistent with the phenotype compatible with type 1 narcolepsy. This study therefore aims to develop new tools to reduce the diagnostic delay. This would be the first study with 7T MRI that could achieve a level of spatial resolution sufficient to highlight volume changes in small brain structures such as the lateral hypothalamus whose narcolepsy-induced changes are not detected by lower resolution MRI.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | January 29, 2026 |
Est. primary completion date | January 29, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria for patients : 1. Diagnosis of narcolepsy type 1 according to the diagnostic criteria of the International Classification of sleep disorders version 3 (ICSD-3, American Academy of Sleep Medicine, 2014) including a mean sleep latency of less than 8 minutes on the iterative sleep latency test associated with at least two direct REM sleep onset and the presence of cataplexy, and a cerebrospinal fluid hypocretin assay of less than 110 pg/ml performed by the reference radioimmunology (RIA) technique. 2. Patient at least 18 years old 3. Patient followed at the Narcolepsy and Rare Hypersomnias Competence Center, Timone Hospital, Marseille 4. Patient having signed an informed consent 5. Patient who is a beneficiary of or affiliated to a social security system Exclusion Criteria for patient: 1. Diagnosis of type 1 narcolepsy according to ICSD-3 criteria but without hypocretin assay 2. Narcolepsy secondary to another neurological pathology or presence of a comorbid neurological pathology (multiple sclerosis, Steinert's myotonic dystrophy, head trauma, epilepsy) 3. Protected patient: pregnant or breastfeeding woman, adult under guardianship or curatorship 4. Contraindication to the realization of a 7T MRI: patient wearing a pacemaker, neurosurgical clips, artificial heart valve, surgical material or metal fragments in the body, dental or hearing prostheses, insulin pump, patient wearing an IUD, claustrophobic patient 5. Patient unable to maintain decubitus position for the duration of the MRI (= 50 minutes) Inclusion criteria for healthy volunteers: 1. Subject 18 years of age or older 2. Subject free of general illness, psychiatric disorders, and infectious, inflammatory, tumor, vascular, degenerative, or traumatic pathology of the central nervous system as determined during the medical interview. 3. Subject who has signed an informed consent ; 4. Subjects who are beneficiaries of or affiliated with a social security plan Exclusion criteria for healthy volunteers: 1. Protected subject: pregnant or breastfeeding woman, adult under guardianship or curatorship 2. Subjects presenting a contraindication to the realization of a 7T MRI: patient with a pacemaker, neurosurgical clips, artificial heart valve, surgical material or metal fragments in the body, dental or auditory prostheses, insulin pump, patient with an IUD, claustrophobic patient 3. Subject unable to maintain a decubitus position for the duration of the MRI (= 50 minutes) |
Country | Name | City | State |
---|---|---|---|
France | Service Epileptologie et Rythmologie Cérébrale, Centre du Sommeil | Marseille |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique Hopitaux De Marseille |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hypothalamic morphological difference | Significant structural size difference between right and left lateral hypothalamus | Month 0 | |
Secondary | Microstructural abnormalities other than volume differences | Significant difference in Diffusion and T2* values in the lateral hypothalamus | Month 0 | |
Secondary | Structural changes in hypothalamic nuclei other than the lateral hypothalamus | Significant difference in volumes and T1 values in other regions of the posterior hypothalamus | Month 0 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05983731 -
A Pilot Observational Study to Assess the Ability of Continuous 'Home' EEG to Accurately Diagnose Narcolepsy and Demonstrate Response to Treatment
|
||
Suspended |
NCT04419792 -
'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy'
|
||
Completed |
NCT05375890 -
Clinical and Neurophysiological Characteristics of Narcolepsy
|
||
Not yet recruiting |
NCT06292598 -
Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients Versus a Control Population
|
||
Recruiting |
NCT06358950 -
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
|
Phase 2 | |
Not yet recruiting |
NCT06457945 -
Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions
|
N/A | |
Not yet recruiting |
NCT06383806 -
Decreasing Nightmares in Adults With Narcolepsy
|
N/A | |
Not yet recruiting |
NCT05914194 -
A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1
|
Phase 3 | |
Completed |
NCT05687903 -
A Study of TAK-861 in Participants With Narcolepsy Type 1
|
Phase 2 | |
Completed |
NCT05709873 -
Narcolepsy Nightmare Study
|
N/A | |
Recruiting |
NCT04483310 -
Meditation-Relaxation (MR Therapy) for Sleep Paralysis.
|
N/A | |
Completed |
NCT04445129 -
Wake and Sleep State Transitions on a Portable Electroencephalogram (EEG) Device in Narcolepsy Type 1 (NT1) and Healthy Participants
|
||
Completed |
NCT05460052 -
Evaluation of the Effectiveness of a Physical Activity Program on the Severity of Narcolepsy
|
||
Completed |
NCT05314556 -
Group Psychotherapy in Narcolepsy Type 1
|
N/A | |
Recruiting |
NCT05816382 -
A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
|
Phase 2/Phase 3 | |
Recruiting |
NCT06336057 -
Mentalizating in Adults Suffering From Narcolepsy Type 1.
|
||
Recruiting |
NCT06251063 -
Improving Social Relationships for Adolescents With Central Disorders of Hypersomnolence
|
N/A | |
Completed |
NCT06241911 -
Transcutaneous Auricular Vagus Nerve Stimulation in Patients With Narcolepsy Type 1
|
N/A |